PURPOSE: The aim of this review is to assess the extent of the use of off-label and/or unlicenced drugs among hospitalised children. METHODS: A systematic search was made in MEDLINE-PubMED for papers published from 1994 to 2012, addressing the prescription of off-label and/or unlicenced drugs for the paediatric population in hospital care. RESULTS: Of the 829 studies retrieved, 34 met the inclusion criteria. Prescriptions ranged from 12.2 to 70.6 % for off-label and from 0.2 to 47.9 % for unlicensed drugs. The percentage of children who received at least one off-label and/or unlicensed drug ranged from 42.0 to 100 %, with newborns being the population that received most of such drugs. Off-label prescriptions were essential for dose modification (7.1-73.1 %) and unlicensed prescriptions for formulation modification purposes (3.6-100 %). CONCLUSIONS: These findings show that: (i) off-label and/or an unlicensed prescribing is widespread among the hospitalised paediatric population worldwide, (ii) there is no consensus on a definition of off-label and/or unlicensed drugs and (iii) preterm newborns receive most off-label and/or unlicensed drugs. By shedding new light on off-label and/or unlicensed drug prescribing, these findings will hopefully contribute to generating new, more effective knowledge about the paediatric population's need for quality drugs that are both safe and efficacious.
PURPOSE: The aim of this review is to assess the extent of the use of off-label and/or unlicenced drugs among hospitalised children. METHODS: A systematic search was made in MEDLINE-PubMED for papers published from 1994 to 2012, addressing the prescription of off-label and/or unlicenced drugs for the paediatric population in hospital care. RESULTS: Of the 829 studies retrieved, 34 met the inclusion criteria. Prescriptions ranged from 12.2 to 70.6 % for off-label and from 0.2 to 47.9 % for unlicensed drugs. The percentage of children who received at least one off-label and/or unlicensed drug ranged from 42.0 to 100 %, with newborns being the population that received most of such drugs. Off-label prescriptions were essential for dose modification (7.1-73.1 %) and unlicensed prescriptions for formulation modification purposes (3.6-100 %). CONCLUSIONS: These findings show that: (i) off-label and/or an unlicensed prescribing is widespread among the hospitalised paediatric population worldwide, (ii) there is no consensus on a definition of off-label and/or unlicensed drugs and (iii) preterm newborns receive most off-label and/or unlicensed drugs. By shedding new light on off-label and/or unlicensed drug prescribing, these findings will hopefully contribute to generating new, more effective knowledge about the paediatric population's need for quality drugs that are both safe and efficacious.
Authors: Dermot R Doherty; Elena Pascuet; Andy Ni; Paul Stewart; William Splinter; Régis Vaillancourt Journal: Can J Anaesth Date: 2010-10-07 Impact factor: 5.063
Authors: Eric Schirm; Hilde Tobi; Eugène P van Puijenbroek; Margje H Monster-Simons; Lolkje T W de Jong-van den Berg Journal: Pharmacoepidemiol Drug Saf Date: 2004-03 Impact factor: 2.890
Authors: Paulo R A Carvalho; Clarissa G Carvalho; Patrícia T Alievi; Jaqueline Martinbiancho; Eliana A Trotta Journal: J Pediatr (Rio J) Date: 2003 Sep-Oct Impact factor: 2.197
Authors: Anke A G Posthumus; Carien C W Alingh; Christian C M Zwaan; Kees K van Grootheest; Lidwien L M Hanff; Bregje B C M Witjes; Geert W 't Jong; Matthijs de Hoog Journal: BMJ Open Date: 2012-08-24 Impact factor: 2.692
Authors: Hui Li; Mark J Canet; John D Clarke; Dean Billheimer; Stavra A Xanthakos; Joel E Lavine; Robert P Erickson; Nathan J Cherrington Journal: Drug Metab Dispos Date: 2017-10-06 Impact factor: 3.922
Authors: Divya Hoon; Matthew T Taylor; Pooja Kapadia; Tobias Gerhard; Brian L Strom; Daniel B Horton Journal: Pediatrics Date: 2019-09-16 Impact factor: 7.124